CD44 and neoplasm: Similarly, Sun et al. incorporated HA (a CD44 ligand) into the KHA-NG nanomedicine to recognize CD44-over-expressed 4T1 cells for tumor cell-targeted NO delivery (Fig. 8B left) [41].